300 related articles for article (PubMed ID: 22531447)
1. Targeting malignant B cells with an immunotoxin against ROR1.
Baskar S; Wiestner A; Wilson WH; Pastan I; Rader C
MAbs; 2012; 4(3):349-61. PubMed ID: 22531447
[TBL] [Abstract][Full Text] [Related]
2. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
Du X; Ho M; Pastan I
J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
Yang J; Baskar S; Kwong KY; Kennedy MG; Wiestner A; Rader C
PLoS One; 2011; 6(6):e21018. PubMed ID: 21698301
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta.
Nagai T; Tanaka M; Tsuneyoshi Y; Xu B; Michie SA; Hasui K; Hirano H; Arita K; Matsuyama T
Cancer Immunol Immunother; 2009 Oct; 58(10):1577-86. PubMed ID: 19238383
[TBL] [Abstract][Full Text] [Related]
7. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
[TBL] [Abstract][Full Text] [Related]
8. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxins in the treatment of refractory hairy cell leukemia.
Kreitman RJ; Pastan I
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
[TBL] [Abstract][Full Text] [Related]
10. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
11. Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis.
Nagai T; Tanaka M; Hasui K; Shirahama H; Kitajima S; Yonezawa S; Xu B; Matsuyama T
Clin Exp Immunol; 2010 Aug; 161(2):348-56. PubMed ID: 20550546
[TBL] [Abstract][Full Text] [Related]
12. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
Alderson RF; Kreitman RJ; Chen T; Yeung P; Herbst R; Fox JA; Pastan I
Clin Cancer Res; 2009 Feb; 15(3):832-9. PubMed ID: 19188153
[TBL] [Abstract][Full Text] [Related]
13. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
14. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z
Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207
[TBL] [Abstract][Full Text] [Related]
15.
Chang J; Liu X; Ren H; Lu S; Li M; Zhang S; Zhao K; Li H; Zhou X; Peng L; Liu Z; Hu P
Mol Pharm; 2021 Jun; 18(6):2285-2297. PubMed ID: 33998814
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
[TBL] [Abstract][Full Text] [Related]
17. An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.
Cai Y; Berger EA
Antiviral Res; 2011 Jun; 90(3):143-50. PubMed ID: 21440007
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer.
Fischer A; Wolf I; Fuchs H; Masilamani AP; Wolf P
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33260619
[TBL] [Abstract][Full Text] [Related]
19. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
[TBL] [Abstract][Full Text] [Related]
20. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
